Insider Trades45 trades
| Date↓ | Side | Ticker↕ | Insider↕ | Role↕ | Shares↕ | Price↕ | Mkt Cap↕ | 52W High↕ | 52W Low↕ | Value↕ | % Chg↕ | Rule↕ | AI View↕ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 18, 2026 | Sell | DTIL | J. Jefferson Smith | Chief Research Officer | 4,925 | $3.84 | $203.1M | -18.19% | +122.95% | $18.9K | -3.07% | 10b5-1 | — |
| Feb 18, 2026 | Sell | DTIL | Dario Scimeca | General Counsel and Secretary | 4,925 | $3.84 | $203.1M | -18.19% | +122.95% | $18.9K | -5.20% | 10b5-1 | — |
| Feb 18, 2026 | Sell | DTIL | John Alexander Kelly | Chief Financial Officer | 8,149 | $3.84 | $203.1M | -18.19% | +122.95% | $31.3K | -4.31% | 10b5-1 | — |
| Feb 18, 2026 | Sell | DTIL | Michael Amoroso | President and CEO | 20,559 | $3.84 | $203.1M | -18.19% | +122.95% | $78.9K | -5.15% | 10b5-1 | — |
| Jan 22, 2026 | Sell | DTIL | Michael Amoroso | President and CEO | 34,799 | $4.17 | $203.1M | -18.19% | +122.95% | $145.1K | -10.31% | 10b5-1 | — |
| Jan 21, 2026 | Sell | DTIL | Dario Scimeca | General Counsel and Secretary | 8,854 | $4.03 | $203.1M | -18.19% | +122.95% | $35.7K | -11.51% | 10b5-1 | — |
| Jan 21, 2026 | Sell | DTIL | J. Jefferson Smith | Chief Research Officer | 10,200 | $4.03 | $203.1M | -18.19% | +122.95% | $41.1K | -6.94% | 10b5-1 | — |
| Jan 21, 2026 | Sell | DTIL | John Alexander Kelly | Chief Financial Officer | 15,213 | $4.03 | $203.1M | -18.19% | +122.95% | $61.3K | -9.38% | 10b5-1 | — |
| Nov 3, 2025 | Sell | DTIL | Dario Scimeca | General Counsel and Secretary | 665 | $6.49 | $203.1M | -18.19% | +122.95% | $4.3K | -2.30% | 10b5-1 | — |
| Nov 3, 2025 | Sell | DTIL | John Alexander Kelly | Chief Financial Officer | 1,303 | $6.49 | $203.1M | -18.19% | +122.95% | $8.5K | -1.66% | 10b5-1 | — |
| Nov 3, 2025 | Sell | DTIL | Michael Amoroso | President and CEO | 3,409 | $6.49 | $203.1M | -18.19% | +122.95% | $22.1K | -2.87% | 10b5-1 | — |
| Jul 3, 2025 | Sell | DTIL | John Alexander Kelly | Chief Financial Officer | 14,827 | $4.26 | $203.1M | -18.19% | +122.95% | $63.2K | -16.79% | — | — |
| Mar 24, 2025 | Sell | DTIL | Michael Amoroso | President and CEO | 964 | $5.56 | $203.1M | -18.19% | +122.95% | $5.4K | -0.87% | 10b5-1 | — |
| Mar 4, 2025 | Sell | DTIL | J. Jefferson Smith | Chief Research Officer | 154 | $4.91 | $203.1M | -18.19% | +122.95% | $756.14 | -0.18% | 10b5-1 | — |
| Mar 4, 2025 | Sell | DTIL | Dario Scimeca | General Counsel and Secretary | 272 | $4.91 | $203.1M | -18.19% | +122.95% | $1.3K | -1.08% | 10b5-1 | — |
| Jan 22, 2025 | Sell | DTIL | Dario Scimeca | General Counsel and Secretary | 8,928 | $4.79 | $203.1M | -18.19% | +122.95% | $42.8K | -10.90% | 10b5-1 | — |
| Jan 22, 2025 | Sell | DTIL | J. Jefferson Smith | Chief Research Officer | 10,287 | $4.79 | $203.1M | -18.19% | +122.95% | $49.3K | -6.70% | 10b5-1 | — |
| Jan 21, 2025 | Sell | DTIL | Michael Amoroso | President and CEO | 36,838 | $4.67 | $203.1M | -18.19% | +122.95% | $172.0K | -10.07% | 10b5-1 | — |
| Dec 27, 2024 | Buy | DTIL | John Alexander Kelly | Chief Financial Officer | 2,113 | $4.75 | $203.1M | -18.19% | +122.95% | $10.0K | +5.55% | — | — |
| Nov 21, 2024 | Buy | DTIL | John Alexander Kelly | Chief Financial Officer | 3,000 | $6.76 | $203.1M | -18.19% | +122.95% | $20.3K | +8.55% | — | — |
| Nov 4, 2024 | Sell | DTIL | Dario Scimeca | General Counsel and Secretary | 588 | $8.19 | $203.1M | -18.19% | +122.95% | $4.8K | -5.66% | 10b5-1 | — |
| Nov 4, 2024 | Sell | DTIL | Michael Amoroso | President and CEO | 3,012 | $8.19 | $203.1M | -18.19% | +122.95% | $24.7K | -7.35% | — | — |
| Jun 10, 2024 | Sell | DTIL | J. Jefferson Smith | Chief Research Officer | 50 | $11.79 | $203.1M | -18.19% | +122.95% | $589.5 | -0.07% | — | — |
| Jun 10, 2024 | Sell | DTIL | Dario Scimeca | General Counsel and Secretary | 93 | $11.79 | $203.1M | -18.19% | +122.95% | $1.1K | -1.36% | 10b5-1 | — |
| May 8, 2024 | Buy | DTIL | Dario Scimeca | General Counsel and Secretary | 833 | $12.00 | $203.1M | -18.19% | +122.95% | $10.0K | +14.67% | — | — |
| May 8, 2024 | Buy | DTIL | J. Jefferson Smith | Chief Research Officer | 833 | $12.00 | $203.1M | -18.19% | +122.95% | $10.0K | +1.23% | — | — |
| May 8, 2024 | Buy | DTIL | John Alexander Kelly | Chief Financial Officer | 8,334 | $12.00 | $203.1M | -18.19% | +122.95% | $100.0K | +36.75% | — | — |
| May 8, 2024 | Buy | DTIL | Michael Amoroso | President and CEO | 8,334 | $12.00 | $203.1M | -18.19% | +122.95% | $100.0K | +60.51% | — | — |
| May 2, 2024 | Sell | DTIL | Dario Scimeca | General Counsel and Secretary | 272 | $10.32 | $203.1M | -18.19% | +122.95% | $2.8K | -3.96% | 10b5-1 | — |
| May 2, 2024 | Sell | DTIL | Alan List | Chief Medical Officer | 290 | $10.32 | $203.1M | -18.19% | +122.95% | $3.0K | -5.04% | 10b5-1 | — |
| May 2, 2024 | Sell | DTIL | Michael Amoroso | President and CEO | 1,526 | $10.32 | $203.1M | -18.19% | +122.95% | $15.7K | -8.15% | 10b5-1 | — |
| Apr 30, 2024 | Sell | DTIL | Alan List | Chief Medical Officer | 238 | $10.03 | $203.1M | -18.19% | +122.95% | $2.4K | -5.90% | 10b5-1 | — |
| Feb 29, 2024 | Buy | DTIL | John Alexander Kelly | Chief Financial Officer | 506 | $18.50 | $203.1M | -18.19% | +122.95% | $9.4K | +2.28% | — | — |
| Feb 29, 2024 | Buy | DTIL | J. Jefferson Smith | Chief Research Officer | 1,160 | $12.14 | $203.1M | -18.19% | +122.95% | $14.1K | +0.63% | — | — |
| Jan 23, 2024 | Sell | DTIL | J. Jefferson Smith | Chief Research Officer | 28,000 | $0.37 | $203.1M | -18.19% | +122.95% | $10.4K | -1.29% | — | — |
| Jan 22, 2024 | Sell | DTIL | Dario Scimeca | General Counsel and Secretary | 21,287 | $0.36 | $203.1M | -18.19% | +122.95% | $7.7K | -7.32% | 10b5-1 | — |
| Jan 22, 2024 | Sell | DTIL | Alan List | Chief Medical Officer | 21,526 | $0.36 | $203.1M | -18.19% | +122.95% | $7.7K | -9.10% | 10b5-1 | — |
| Jan 22, 2024 | Sell | DTIL | Michael Amoroso | President and CEO | 137,390 | $0.36 | $203.1M | -18.19% | +122.95% | $49.5K | -13.38% | 10b5-1 | — |
| Nov 3, 2023 | Sell | DTIL | Dario Scimeca | General Counsel and Secretary | 16,023 | $0.40 | $203.1M | -18.19% | +122.95% | $6.4K | -6.70% | 10b5-1 | — |
| Nov 3, 2023 | Sell | DTIL | Michael Amoroso | President and CEO | 125,025 | $0.40 | $203.1M | -18.19% | +122.95% | $50.0K | -13.61% | 10b5-1 | — |
| Aug 31, 2023 | Buy | DTIL | J. Jefferson Smith | Chief Research Officer | 5,175 | $0.39 | $203.1M | -18.19% | +122.95% | $2.0K | +0.27% | — | — |
| Aug 31, 2023 | Buy | DTIL | Dario Scimeca | General Counsel and Secretary | 5,443 | $0.39 | $203.1M | -18.19% | +122.95% | $2.1K | +7.95% | — | — |
| Aug 31, 2023 | Buy | DTIL | John Alexander Kelly | Chief Financial Officer | 5,951 | $0.39 | $203.1M | -18.19% | +122.95% | $2.3K | +1.55% | — | — |
| Aug 18, 2023 | Buy | DTIL | John Alexander Kelly | Chief Financial Officer | 90,000 | $0.48 | $203.1M | -18.19% | +122.95% | $43.2K | +30.68% | — | — |
| Aug 18, 2023 | Buy | DTIL | John Alexander Kelly | Chief Financial Officer | 90,000 | $0.48 | $203.1M | -18.19% | +122.95% | $43.2K | +30.68% | — | — |